StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Equity method investment in Arcus Biosciences, Inc. by Quarter

Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M) ($M)

QuarterlyAnnual

Gilead Sciences Equity method investment in Arcus Biosciences, Inc.: $969M in Q2 2026. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
969
Period ended Jun 30, 2026
Change on a year earlier
–
History
14 quarters
Since Q4 2020
Sources
12
Documents cited below

Where the Q2 2026 figure comes from

“|| Equity method investment in Arcus Biosciences, Inc. – fair value option | 969 | 749”

Source: Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Note 3 Fair Value & Note 4 Equity Securities.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEquity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026969–Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2026Mar 31, 2026679–Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025749+67.2%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q3 2025Sep 30, 2025427–Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q4 2024Dec 31, 2024448–Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2023Sep 30, 2023266-26.3%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗
Q2 2023Jun 30, 2023301-14.0%Form 10-Q (gild-20230630.htm, filed 2023-08-04) ↗
Q1 2023Mar 31, 2023252-42.2%Form 10-Q (gild-20230331.htm, filed 2023-05-03) ↗
Q4 2022Dec 31, 2022286-48.8%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗
Q3 2022Sep 30, 2022361–Form 10-Q (gild-20220930.htm, filed 2022-11-02) ↗
Q2 2022Jun 30, 2022350–Form 10-Q (gild-20220630.htm, filed 2022-08-08) ↗
Q1 2022Mar 31, 2022436–Form 10-Q (gild-20220331.htm, filed 2022-05-04) ↗
Q4 2021Dec 31, 2021559+163.7%Form 10-K (gild-20221231.htm, filed 2023-02-22) ↗
Q4 2020Dec 31, 2020212–Form 10-K (gild-20211231.htm, filed 2022-02-23) ↗

Cite this data

StockData. (2026). Gilead Sciences Equity method investment in Arcus Biosciences, Inc. ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/eq-inv-arcus

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.